Therapeutic drug monitoring of adalimumab in hidradenitis suppurativa: a prospective observational study - PubMed
4 hours ago
- #hidradenitis suppurativa
- #adalimumab
- #therapeutic drug monitoring
- Adalimumab (ADA) is effective for moderate to severe hidradenitis suppurativa (HS), but nearly half of patients may lose response to standard doses.
- A prospective observational study was conducted to establish therapeutic thresholds for ADA levels in HS patients, aiming for personalized treatment.
- Patients were stratified by response levels (low, partial, high), with ADA serum concentrations positively correlating with clinical response.
- Low responders had significantly lower ADA concentrations compared to partial and high responders, and drug clearance was inversely correlated with ADA levels.
- Optimal thresholds identified were 10.7 μg/mL for ADA concentration and 0.5 L/day for clearance, suggesting therapeutic drug monitoring can optimize ADA therapy in HS.